Bimodal fluorescence–magnetic resonance imaging (MRI) technique has shown great utilities in bioassays because it combines the advantages of both optical imaging and MRI to provide more sufficient information over any modality alone. In this work, on the basis of a MnO 2 nanosheet–Ru(II) complex nanoarchitecture, a bimodal phosphorescence–MRI nanoprobe for glutathione (GSH) has been constructed. The nanoprobe, Ru(BPY) 3 @MnO 2, was constructed by integrating MnO 2 nanosheets with a phosphorescent Ru(II) complex [Ru(BPY) 3 ](PF 6 ) 2 (BPY = 2,2′-bipyridine), which resulted in complete phosphorescence quenching of the Ru(II) complex, accompanied by very low longitudinal and transverse relaxivity. Upon exposure to GSH, the reduction of MnO 2 nanosheets by GSH triggers a recovery of phosphorescence and simultaneously produces a number of Mn 2+ ions, a perfect MRI contrast agent. The as-prepared nanoprobe showed good water dispersion and biocompatibility and a rapid, selective, and sensitive response toward GSH in the phosphorescence and MR detection modes. The practicability of the nanoprobe was proved by time-gated luminescence assay of GSH in human serum, phosphorescent imaging of endogenous GSH in living cells, zebrafish, and tumor-bearing mice, as well as the MRI of GSH in tumor-bearing mice. The research outcomes suggested the potential of Ru(BPY) 3 @MnO 2 for the bimodal phosphorescence–MRI sensing of GSH in vitro and in vivo.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: